Login / Signup

New advances in the management of cytomegalovirus in allogeneic haemopoietic stem cell transplantation.

Michelle K YongDavid GottliebJulian LindsayJen KokWilliam RawlinsonMonica SlavinDavid RitchieAshish BajelAndrew Grigg
Published in: Internal medicine journal (2021)
Cytomegalovirus (CMV) viraemia continues to be a frequent complication in the post-haemopoietic stem cell transplantation period despite a low incidence of CMV end-organ disease. Several significant advances in the understanding and management of CMV infection have occurred in the last few years including improved diagnostics, monitoring of CMV immunity, availability of novel anti-CMV drugs, and emerging use of immunotherapies including CMV-specific T-cell infusions. In addition to reviewing these advances we also explore some of the more practical prescribing issues of the older and newer CMV drugs including cost, toxicity and drug interactions to help clinicians navigate this new era of CMV management.
Keyphrases
  • stem cell transplantation
  • high dose
  • primary care
  • emergency department
  • epstein barr virus
  • physical activity
  • middle aged
  • adverse drug